Receptor Tyrosine Kinase Expression in BRCA Mutation Carriers: An Opportunity for Prevention of Invasive Breast Cancer

INTRODUCTION: Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies, with a median survival of five months and no effective therapies. The ubiquitineproteasome pathway, which plays an integral role in the mechanisms underlying carcinogenesis, is an attractive molecular target for cancer therapy. Furthermore, suppression of the anti-apoptotic protein Survivin has been shown to enhance proteasome inhibitor-mediated cytotoxicity. The aim of the present study was to investigate the anticancer effects on ATC of second-generation proteasome inhibitor, Carfilzomib, alone and in combination with Survivin inhibitor YM115.